Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
498.15
+2.89 (+0.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
August 29, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
August 17, 2023
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.
Via
MarketBeat
Topics
ETFs
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
August 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Biotech Stocks to Buy for Long-Term Gains
July 13, 2023
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Vertex to Announce Second Quarter 2023 Financial Results on August 1
June 30, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
June 30, 2023
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June.
Via
MarketBeat
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
June 26, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
June 23, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Is the Biotech Industry (IBB) Poised For A Major Breakout?
June 12, 2023
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range.
Via
MarketBeat
Topics
ETFs
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
June 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
June 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
June 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
May 30, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
MarketBeat Week in Review – 5/15 - 5/19
May 20, 2023
Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Economy
Electric Vehicles
Interest Rates
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
Via
MarketBeat
Exposures
Product Safety
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
May 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports First Quarter 2023 Financial Results
May 01, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
April 26, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
April 25, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Records 52-Week High Thursday Morning
April 13, 2023
Via
Investor Brand Network
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Wednesday Session
April 12, 2023
Via
Investor Brand Network
Vertex to Announce First Quarter 2023 Financial Results on May 1
April 10, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
April 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Small Financial Software Makers Showing Strong Chart Action
March 28, 2023
Financial software firms Intapp, Vertex, and GuidewIre are headed toward greater profitability and also boast strong chart action.
Via
MarketBeat
Bullish News May Push Vertex Pharmaceuticals Above 52-Week High
March 28, 2023
A recent announcement by Vertex Pharmaceuticals is confirming a technical signal that could allow the stock to make a new run at its 52-week high
Via
MarketBeat
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
March 27, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
March 16, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
March 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
February 21, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.